Trial Profile
A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs ARQ 761 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 31 May 2022 Status changed from suspended to discontinued. Reason the study was stopped: The study placed on temporarily hold to enrollment due to quality testing necessary for the study drug.
- 11 Oct 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 16 Oct 2019 Status changed from recruiting to suspended.